Pidnarulex (CX-5461) demonstrates acceptable tolerability and preliminary efficacy in end-stage oncology patients with BRCA1/2 or PALB2 mutations, even after PARP inhibitor failure.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.